TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16023214

Group type: EXPERIMENTAL
Intervention: Early treatment for high-risk prethreshold ROP (n = 317 eyes)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional management for high-risk prethreshold ROP (n = 307 eyes)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional management when threshold ROP developed
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional management when regression without treatment occurred
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Early treatment at high-risk prethreshold ROP with abnormal angle of temporal retinal vessels or macular ectopia
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Early treatment at high-risk prethreshold ROP with no retinal residua
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional management with abnormal angle of temporal retinal vessels or macular ectopia
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional management with no retinal residua
Number of subjects: 401
Study: 11920310

Group type: EXPERIMENTAL
Intervention: high-dose IFN
Number of subjects: 22
Study: 10334540

Group type: EXPERIMENTAL
Intervention: CDDP 50 mg/m2, GEM 1,000 mg/m2, and VNR 25 mg/m2 on days 1 and 8 of an every-3-weeks cycle (arm A)
Number of subjects: 111

Group type: COMPARATOR
Intervention: CDDP 80 mg/m2, epirubicin 80 mg/m2, and vindesine 3 mg/m2 on day 1 every 4 weeks, plus lonidamine orally 150 mg three times daily (arm B)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: CDDP-GEM-VNR combination (arm A)
Number of subjects: 111

Group type: COMPARATOR
Intervention: CDDP-epirubicin-vindesine-lonidamine combination (arm B)
Number of subjects: 111
Study: 8603548

Group type: EXPERIMENTAL
Intervention: Laparoscopic rectopexy
Number of subjects: 0
Study: 1669483

Group type: EXPERIMENTAL
Intervention: 5 mg/ml (0.5%) timolol maleate
Number of subjects: 64

Group type: COMPARATOR
Intervention: No drugs (comparison group)
Number of subjects: 64
Study: 7079067

Group type: EXPERIMENTAL
Intervention: Heat condition (cortical temperature raised by 7 degrees F)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo condition (helmet with no external heat applied)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control condition (no specific details provided)
Number of subjects: 6
Study: 31529194

Group type: EXPERIMENTAL
Intervention: Prevena™ negative pressure wound therapy
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: PICO™ negative pressure wound therapy
Number of subjects: 271

Group type: COMPARATOR
Intervention: Standard surgical dressings (control)
Number of subjects: 271
Study: 28273318

Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA) plus low vision rehabilitation with an occupational therapist (OT‐LVR)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 188
Study: 26093032

Group type: EXPERIMENTAL
Intervention: RUL Brief Pulse (BP) ECT (1.0 ms)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: RUL Ultrabrief Pulse (UBP) ECT (0.3-0.4 ms)
Number of subjects: 87
Study: 24446026

Group type: EXPERIMENTAL
Intervention: Immediate Cediranib
Number of subjects: 12

Group type: COMPARATOR
Intervention: Delayed Cediranib
Number of subjects: 12
Study: 22825366

Group type: EXPERIMENTAL
Intervention: Non-celiac wheat sensitivity (WS) diagnosed by double-blind placebo-controlled challenge
Number of subjects: 276

Group type: COMPARATOR
Intervention: Celiac disease (CD) patients
Number of subjects: 276

Group type: COMPARATOR
Intervention: Irritable bowel syndrome (IBS) patients
Number of subjects: 276
Study: 19569890

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 0
Study: 17766764

Group type: EXPERIMENTAL
Intervention: Self-reported insight
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Self-reported insight (awareness of illness dimension)
Number of subjects: 67
Study: 15080377

Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 1650
Study: 12053331

Group type: EXPERIMENTAL
Intervention: 5-minute compression (group 1)
Number of subjects: 130

Group type: COMPARATOR
Intervention: 15-minute compression (group 2)
Number of subjects: 130
Study: 9491788

Group type: EXPERIMENTAL
Intervention: ZD1694 (Tomudex®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: irinotecan (Campto®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: oxaliplatin (L-OHP®) in combination with continuous infusion 5-FU
Number of subjects: 0
Study: 7857999

Group type: EXPERIMENTAL
Intervention: Continuation of weekly sessions of supervised group physical therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Unsupervised daily exercises at home (discontinuation group)
Number of subjects: 68
Study: 2892520

Group type: EXPERIMENTAL
Intervention: Temazepam elixir 30 mg by mouth
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diazemuls i.v. titrated to a maximum dose of 20 mg
Number of subjects: 50
Study: 31308848

Group type: EXPERIMENTAL
Intervention: Left anodal tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right anodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 28359279

Group type: EXPERIMENTAL
Intervention: High-volume irrigation (HV)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Low-volume irrigation (LV)
Number of subjects: 300
Study: 26187303

Group type: EXPERIMENTAL
Intervention: Mobile Insulin Titration Intervention (MITI) using SMS text messages and phone calls
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care arm (standard clinic care for insulin titration)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Mobile Insulin Titration Intervention (MITI)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 61
Study: 22835990

Group type: COMPARATOR
Intervention: Self-reported depressive symptoms (BDI score ≥ 19)
Number of subjects: 2704

Group type: COMPARATOR
Intervention: Clinical depression
Number of subjects: 2704
Study: 17145434

Group type: EXPERIMENTAL
Intervention: External valvuloplasty of the femoral vein combined with surgery of the superficial venous system (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgery of the superficial venous system alone (Group B)
Number of subjects: 40
Study: 12705569

Group type: EXPERIMENTAL
Intervention: Children from stigmatized ethnic groups aware of broadly held stereotypes
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Children from academically stigmatized ethnic groups (African Americans and Latinos)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Children ages 6 to 10
Number of subjects: 202
Study: 10551711

Group type: EXPERIMENTAL
Intervention: 120-J rectilinear biphasic shock
Number of subjects: 184

Group type: COMPARATOR
Intervention: 200-J damped sine wave monophasic shock
Number of subjects: 184
Study: 8901852

Group type: EXPERIMENTAL
Intervention: 5 years of tamoxifen
Number of subjects: 3545

Group type: COMPARATOR
Intervention: 2 years of tamoxifen
Number of subjects: 3545
Study: 1687131

Group type: EXPERIMENTAL
Intervention: Salmeterol 12.5 micrograms b.d.
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms b.d.
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms b.d.
Number of subjects: 692

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study: 6336975

Group type: EXPERIMENTAL
Intervention: Allopurinol pretreatment (300 mg two hours prior to and 10 hours after 5-FU)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Allopurinol pretreatment (300 mg every 8 hours for 4 doses starting 24 hours before 5-FU)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Allopurinol pretreatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: 5-FU administration
Number of subjects: 23
Study: 31141410

Group type: EXPERIMENTAL
Intervention: Coping with and Caring for infants with special needs (COPCA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Typical infant physiotherapy
Number of subjects: 43
Study: 30926996

Group type: EXPERIMENTAL
Intervention: School Feeding Program (SFP) providing multiple-micronutrient-fortified meals
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Take-Home Ration (THR) nutritionally equivalent to SFP
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Take-Home Ration (THR)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: School Feeding Program (SFP)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Control group with no FFE
Number of subjects: 627
Study: 28372046

Group type: EXPERIMENTAL
Intervention: Word recognition training with target and masker differing in gender
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Word recognition training with same‐gender target and masker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender recognition training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control with no training
Number of subjects: 0
Study: 26443653

Group type: EXPERIMENTAL
Intervention: Strengths Model Case Management (SMCM)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (matched control)
Number of subjects: 86
Study: 23622444

Group type: EXPERIMENTAL
Intervention: Earlier treated eyes (high-risk prethreshold ROP)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventionally managed eyes (treatment only if threshold ROP developed)
Number of subjects: 401
Study: 20725062

Group type: EXPERIMENTAL
Intervention: EGCG (Teavigo) 135 mg/capsule, 3 capsules/day for 48 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EGCG (Teavigo)
Number of subjects: 16
Study: 19458432

Group type: EXPERIMENTAL
Intervention: Modulated middle frequency alternating current (MFAC) stimulation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard low frequency rectangular pulse (LFRP) stimulation
Number of subjects: 13
Study: 17123343

Group type: EXPERIMENTAL
Intervention: TRIAC 0.1%
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 15587767

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 3713
Study: 11733254

Group type: EXPERIMENTAL
Intervention: Two Surodex pellets inserted in the anterior chamber (AC) of 35 eyes (group B)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Two Surodex pellets inserted in the ciliary sulcus of 36 eyes (group C)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Dexamethasone eyedrops (0.1%) four times daily for 4 weeks (group A)
Number of subjects: 104
Study: 9441102

Group type: EXPERIMENTAL
Intervention: KRM 1648 (KRM) at 20 micrograms/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifabutin (RBT) at 20 micrograms/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KRM 1648 (KRM) at 0.2 microgram/ml combined with 2.0 micrograms/ml of CLA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifabutin (RBT) at 0.2 microgram/ml combined with 2.0 micrograms/ml of CLA
Number of subjects: 0
Study: 7950502

Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day, tdd) with 500 mg/day of calcium
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo with 500 mg/day of calcium
Number of subjects: 39
Study: 2888551

Group type: EXPERIMENTAL
Intervention: Thyrotrophin binding inhibiting (TBII) antibodies
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thyroid stimulating (TSAb) antibodies
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thyroid growth stimulating (TGI) antibodies
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TBII and TSAb
Number of subjects: 60
Study: 31540869

Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery technique
Number of subjects: 534

Group type: COMPARATOR
Intervention: Cold dissection technique
Number of subjects: 534
Study: 30061588

Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium animalis subsp. lactis Bl‐04
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rhinovirus infection
Number of subjects: 0
Study: 28490348

Group type: EXPERIMENTAL
Intervention: MammaTyper® test for determining mRNA expression levels of ERBB2, ESR1, PGR, and MKI67
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MammaTyper® test for binary single-marker results (positive/negative)
Number of subjects: 10
Study: 26292908

Group type: EXPERIMENTAL
Intervention: POCT urine culture and susceptibility testing and targeted treatment
Number of subjects: 750

Group type: COMPARATOR
Intervention: POCT urine culture without susceptibility testing and empirical treatment
Number of subjects: 750
Study: 23811325

Group type: EXPERIMENTAL
Intervention: Sleep restriction involving a fixed sleep-wake schedule, reducing time in bed (TIB) by 60 minutes below baseline for older long sleepers.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control treatment involving no sleep restriction but a fixed sleep schedule for older average sleepers.
Number of subjects: 200
Study: 21399490

Group type: EXPERIMENTAL
Intervention: Propofol (4 mg · kg⁻¹ · h⁻¹)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Desflurane (1 minimum alveolar concentration)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1 minimum alveolar concentration)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All anesthetics (Propofol, Desflurane, Sevoflurane)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Desflurane and Sevoflurane
Number of subjects: 63
Study: 18721764

Group type: EXPERIMENTAL
Intervention: palifermin (240 microg/kg to 720 microg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 16837678

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg on the first day, then 100 mg per day for four days)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 15570767

Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 14

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 14
Study: 11083601

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9036434

Group type: EXPERIMENTAL
Intervention: 21-G pencil-point needle (Sprotte)
Number of subjects: 412

Group type: COMPARATOR
Intervention: 22-G Quincke needle
Number of subjects: 412
Study: 1573199

Group type: EXPERIMENTAL
Intervention: Cognitive training program based on figural relations, a component of fluid intelligence.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 3887210

Group type: EXPERIMENTAL
Intervention: Platelet antiaggregant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 0
Study: 30791895

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU every 2 weeks) plus probiotic (8 × 10^9 CFU/day)
Number of subjects: 60
Study: 28177459

Group type: EXPERIMENTAL
Intervention: NOAC
Number of subjects: 22198
Study: 25236682

Group type: EXPERIMENTAL
Intervention: Wound closure in flexion position
Number of subjects: 85

Group type: COMPARATOR
Intervention: Wound closure in extension position
Number of subjects: 85
Study: 25365713

Group type: EXPERIMENTAL
Intervention: Surgical treatment for spinal stenosis
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Surgical treatment for degenerative spondylolisthesis (DS)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Surgical treatment for intervertebral disc herniation (IDH)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Nonoperative treatment for degenerative spondylolisthesis (DS)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Nonoperative treatment for intervertebral disc herniation (IDH)
Number of subjects: 634
Study: 22295835

Group type: EXPERIMENTAL
Intervention: SXDZ-100
Number of subjects: 64

Group type: COMPARATOR
Intervention: SDZ-II
Number of subjects: 64
Study: 21152844

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 160
Study: 17347061

Group type: EXPERIMENTAL
Intervention: Beclomethasone diproprionate enema
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Beclomethasone diproprionate foam
Number of subjects: 99

Group type: COMPARATOR
Intervention: Mesalazine enema
Number of subjects: 99

Group type: COMPARATOR
Intervention: Mesalazine foam
Number of subjects: 99
Study: 16092810

Group type: EXPERIMENTAL
Intervention: CAM education and research integration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Setting educational standards for CAM
Number of subjects: 0
Study: 12222716

Group type: EXPERIMENTAL
Intervention: Oral midazolam sedation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rectal midazolam sedation
Number of subjects: 50
Study: 10512347

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7734163

Group type: EXPERIMENTAL
Intervention: Prophylactic therapy with amoxicillin and clavulanic acid for 24 hours
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Prophylactic therapy with amoxicillin and clavulanic acid for 5 days
Number of subjects: 170
Study: 1979288

Group type: EXPERIMENTAL
Intervention: Buserelin (Gn-RH superagonist)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (post-buserelin observation)
Number of subjects: 48
Study: 7004556

Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 98

Group type: COMPARATOR
Intervention: Paracetamol/dextropropoxyphene combination
Number of subjects: 98
Study: 29399709

Group type: EXPERIMENTAL
Intervention: Undistracted group (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Distracted group (Group 2)
Number of subjects: 20
Study: 27015801

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 30 L/min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Long-term oxygen therapy (LTOT) at 2‐4 L/min
Number of subjects: 30
Study: 25769334

Group type: EXPERIMENTAL
Intervention: Reinforced health education
Number of subjects: 106

Group type: COMPARATOR
Intervention: Traditional health education
Number of subjects: 106
Study: 23841289

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 30
Study: 20579583

Group type: EXPERIMENTAL
Intervention: Coronary artery revascularization before elective vascular surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Baseline homocysteine level
Number of subjects: 30
Study: 18256366

Group type: EXPERIMENTAL
Intervention: Active treatment (blood pressure lowering regimen)
Number of subjects: 5671

Group type: EXPERIMENTAL
Intervention: Carriers of epsilon 2 or epsilon 4 allele of the APOE polymorphism
Number of subjects: 5671

Group type: EXPERIMENTAL
Intervention: Carriers of epsilon 2 or epsilon 4 allele in Asian patients
Number of subjects: 5671

Group type: EXPERIMENTAL
Intervention: Carriers of epsilon 2 or epsilon 4 allele in Europeans
Number of subjects: 5671
Study: 16456897

Group type: EXPERIMENTAL
Intervention: Oltipraz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12030636

Group type: EXPERIMENTAL
Intervention: Prior experiences expectation measure
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Ideal referents expectation measure
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Market-based expectations measure
Number of subjects: 315
Study: 9835830

Group type: EXPERIMENTAL
Intervention: Crest MultiCare with 3.3% pyrophosphate
Number of subjects: 456

Group type: COMPARATOR
Intervention: Crest Regular Paste or Crest Tartar Protection Paste with 5.0% pyrophosphate
Number of subjects: 456
Study: 8007590

Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD) with ketoacids (KA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD) with essential amino acids (EAA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD)
Number of subjects: 8
Study: 2643188

Group type: EXPERIMENTAL
Intervention: Topical application of 2 grams of ampicillin at the site of incision at closure
Number of subjects: 193

Group type: COMPARATOR
Intervention: No topical application of ampicillin
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Topical application of ampicillin
Number of subjects: 193
Study: 8291727

Group type: EXPERIMENTAL
Intervention: Eltanolone
Number of subjects: 175

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 175

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 175
Study: 377739

Group type: EXPERIMENTAL
Intervention: Aspirin 2.4 g daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Allopurinol 200 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31485815

Group type: EXPERIMENTAL
Intervention: Pediatric Developmental Passport
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo card
Number of subjects: 40
Study: 28081848

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 27696367

Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) infection
Number of subjects: 22215

Group type: COMPARATOR
Intervention: Control group (no HBV infection)
Number of subjects: 22215
Study: 24684456

Group type: EXPERIMENTAL
Intervention: Chewable tablet (TAB)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Oil-emulsified drop (DROP)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Encapsulated powder (CAP)
Number of subjects: 66
Study: 21933939

Group type: EXPERIMENTAL
Intervention: Final Kissing Ballooning (FKB)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Non-Final Kissing Ballooning (non-FKB)
Number of subjects: 1065
Study: 19120740

Group type: EXPERIMENTAL
Intervention: Interpersonal social rhythm therapy
Number of subjects: 1
Study: 17634566

Group type: EXPERIMENTAL
Intervention: Affect labeling task
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gender labeling control task
Number of subjects: 27
Study: 15117896

Group type: EXPERIMENTAL
Intervention: Metformin (1.5-2.55 g/day)
Number of subjects: 126
Study: 11985913

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (median dose 80 microg four times a day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 11229216

Group type: EXPERIMENTAL
Intervention: Bed rest for 24 hours after lumbar puncture
Number of subjects: 208

Group type: COMPARATOR
Intervention: Ambulant (no bed rest)
Number of subjects: 208